Insider Transactions in Q2 2023 at Edgewise Therapeutics, Inc. (EWTX)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 22
2023
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+25.63%
|
$0
$0.71 P/Share
|
|
May 02
2023
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
3,203
-30.75%
|
$25,624
$8.9 P/Share
|
|
May 02
2023
|
Joanne M. Donovan CMO |
SELL
Open market or private sale
|
Direct |
3,254
-24.63%
|
$26,032
$8.9 P/Share
|
|
May 02
2023
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,602
-0.9%
|
$12,816
$8.9 P/Share
|
|
May 02
2023
|
R Michael Carruthers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,336
-7.65%
|
$10,688
$8.9 P/Share
|
|
May 02
2023
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
1,897
-22.42%
|
$15,176
$8.9 P/Share
|
|
May 02
2023
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,747
-19.93%
|
$13,976
$8.9 P/Share
|
|
May 01
2023
|
Kevin Koch President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,416
+50.0%
|
-
|
|
May 01
2023
|
Joanne M. Donovan CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,416
+44.08%
|
-
|
|
May 01
2023
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,208
+2.85%
|
-
|
|
May 01
2023
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,208
+22.97%
|
-
|
|
May 01
2023
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,208
+38.1%
|
-
|
|
May 01
2023
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,208
+37.27%
|
-
|